Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 +2.31%58 Current Ratio is 4.68 as of Dec. 2025, which is 64% above its 10-year median of 2.86. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Medigen Biotechnology ranks better than 55.28% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Medigen Biotechnology's current ratio for the quarter that ended in Dec. 2025 was 4.68.
Medigen Biotechnology has a current ratio of 4.68. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Medigen Biotechnology's Current Ratio or its related term are showing as below:
ROCO:3176'
s Current Ratio Range Over the Past 10 Years
Min: 1.41 Med: 2.86 Max: 6.4
Current: 4.68
During the past 13 years, Medigen Biotechnology's highest Current Ratio was 6.40. The lowest was 1.41. And the median was 2.86.
ROCO:3176's Current Ratio is ranked better than 55.28% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:3176: 4.68
Medigen Biotechnology (ROCO:3176) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Medigen Biotechnology Current Ratio Related Terms
Medigen Biotechnology Current Ratio Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Current Ratio of 4.68 as of Dec. 2025. This is 64% above median its historical median of 2.86. Over the past decade, Medigen Biotechnology's Current Ratio has ranged from 1.41 to 6.40. According to the industry distribution chart, Medigen Biotechnology ranks #631 out of 1411 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Medigen Biotechnology's Current Ratio too high?
Medigen Biotechnology's current Current Ratio of 4.68 is 64% above median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 6.40. The Biotechnology industry median Current Ratio is 3.88. Medigen Biotechnology's value of 4.68 is 20.6% above this industry median. Based on the distribution chart, Medigen Biotechnology ranks #631 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #631 out of 1411 companies for Current Ratio. This puts Medigen Biotechnology in the upper half of its industry. The industry median Current Ratio is 3.88. Medigen Biotechnology's value of 4.68 is 20.6% above this benchmark. Historically, Medigen Biotechnology's own Current Ratio has ranged from 1.41 to 6.40 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 3.88, Medigen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current Current Ratio of 4.68 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Current Ratio is 4.68, which is 64% above median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current Current Ratio is 4.68, which is 64% above median its 10-year median of 2.86 and 20.6% above the Biotechnology industry median of 3.88. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Current Ratio is 4.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63.
GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3176:
Current Ratio: 4.68 (64% above median its 10-year median of 2.86)
GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
Industry Position: 20.6% above the Biotechnology median (#631 of 1411)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
